Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

News
2021
2020
Archive

June 30, 2021

Novome Biotechnologies Initiates Phase 1/2a Study to Evaluate Therapeutically Engineered Bacteria for the Treatment of Enteric Hyperoxaluria
June 29, 2021

Pear Therapeutics Announces First Participant Enrolled in National Institutes of Health Clinical Trial Investigating Combinations of Pharmacological and Behavioral Interventions to Treat Opioid Use Disorder
June 28, 2021

IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
June 28, 2021

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
June 22, 2021

Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer
June 22, 2021

Boston IVF Partners with TMRW Life Sciences to Adopt State-of-the-Art Technology for the Safe Management of Eggs and Embryos
June 22, 2021

Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics
June 17, 2021

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs
June 15, 2021

CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes
June 11, 2021

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

© 2021 5AM Venture Management LLC